You are here
CERID Bibliography
Export 31 results:
Author Title Type [ Year
] Filters: Keyword is Trypanosoma brucei brucei [Clear All Filters]
Distinct states of methionyl-tRNA synthetase indicate inhibitor binding by conformational selection. Structure. 2012 ;20(10):1681-91.
Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization. J Med Chem. 2012 ;55(14):6342-51.
Crystal structures of three protozoan homologs of tryptophanyl-tRNA synthetase. Mol Biochem Parasitol. 2011 ;177(1):20-8.
. An essential farnesylated kinesin in Trypanosoma brucei. PLoS One. 2011 ;6(11):e26508.
Screening a fragment cocktail library using ultrafiltration. Anal Bioanal Chem. 2011 ;401(5):1585-91.
Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei Infection in Mice. Antimicrob Agents Chemother. 2011 ;55(5):1982-9.
. Structure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structure-activity relationships with Trypanosoma brucei GSK-3. Mol Biochem Parasitol. 2011 ;176(2):98-108.
. Trypanosoma brucei glycogen synthase kinase-3, a target for anti-trypanosomal drug development: a public-private partnership to identify novel leads. PLoS Negl Trop Dis. 2011 ;5(4):e1017.
The crystal structure and activity of a putative trypanosomal nucleoside phosphorylase reveal it to be a homodimeric uridine phosphorylase. J Mol Biol. 2010 ;396(5):1244-59.
Crystal structures of trypanosomal histidyl-tRNA synthetase illuminate differences between eukaryotic and prokaryotic homologs. J Mol Biol. 2010 ;397(2):481-94.
Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. Mol Microbiol. 2008 ;68(1):37-50.
Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother. 2008 ;52(10):3710-7.
Structure of a Trypanosoma brucei alpha/beta-hydrolase fold protein with unknown function. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008 ;64(Pt 6):474-8.
. C-terminal proteolysis of prenylated proteins in trypanosomatids and RNA interference of enzymes required for the post-translational processing pathway of farnesylated proteins. Mol Biochem Parasitol. 2007 ;153(2):115-24.
. Gene conversion is a convergent strategy for pathogen antigenic variation. Trends Parasitol. 2007 ;23(9):408-13.
Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. J Med Chem. 2006 ;49(20):5939-46.
Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents. J Med Chem. 2004 ;47(2):432-45.
. Isothiazole dioxides: synthesis and inhibition of Trypanosoma brucei protein farnesyltransferase. Bioorg Med Chem Lett. 2002 ;12(16):2217-20.
. Trypanosoma brucei prenylated-protein carboxyl methyltransferase prefers farnesylated substrates. Biochem J. 2002 ;367(Pt 3):809-16.
Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design. J Med Chem. 2001 ;44(13):2080-93.
. Cloning and functional characterization of a Trypanosoma brucei lanosterol 14alpha-demethylase gene. Mol Biochem Parasitol. 2001 ;117(1):115-7.
. Adenosine analogues as inhibitors of Trypanosoma brucei phosphoglycerate kinase: elucidation of a novel binding mode for a 2-amino-N(6)-substituted adenosine. J Med Chem. 2000 ;43(22):4135-50.
. Cloning and heterologous expression of the Trypanosoma brucei lanosterol synthase gene. Mol Biochem Parasitol. 2000 ;110(2):399-403.
. Cloning, heterologous expression, and distinct substrate specificity of protein farnesyltransferase from Trypanosoma brucei. J Biol Chem. 2000 ;275(29):21870-6.
. Structure-based design of submicromolar, biologically active inhibitors of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase. Proc Natl Acad Sci U S A. 1999 ;96(8):4273-8.
